Knott David M Jr
Quarter end: Sep 30, 2026 · Filed with SEC: Nov 12, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$182.8M2026 Q3
Positions80
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.66.7%
What Changed This Quarter?
Top Holdings
GOOG
Alphabet
17.0%
APO
Apollo Global Management
14.3%
IOVA
Iovance Biotherapeutics
9.4%
XERS
Xeris Biopharma
5.2%
SNDX
Syndax Pharmaceuticals
4.4%
TVTX
Travere Therapeutics
4.2%
BBIO
BridgeBio Pharma
3.6%
JPM
JPMorgan Chase
3.1%
New / Increased
8 new · 12 increased
ORKANEW
Oruka Therapeutics
0.5%
COLLNEW
Collegium Pharmaceutical
0.5%
DYNNEW
Dyne Therapeutics
0.5%
DWDPEURNEW
DuPont de Nemours
0.3%
EWTXNEW
Edgewise Therapeutics
0.2%
ELVN
Enliven Therapeutics
0.7%
+367.5%
COGT
Cogent Biosciences
2.4%
+22.5%
CDNA
CareDx
0.8%
+62.6%
Reduced / Exited
18 reduced · 12 sold out
IOVA
Iovance Biotherapeutics
9.4%
-27.2%
PTGX
Protagonist Therapeutics
2.5%
-48.1%
AGIO
Agios Pharmaceutical
0.9%
-48.4%
TVTX
Travere Therapeutics
4.2%
-11.8%
RZLT
Rezolute
0.4%
-56.9%
Catalyst Phar…EXIT
Catalyst Pharmaceuticals
1.9%
ATRCEXIT
AtriCure
0.8%
ARDXEXIT
Ardelyx
0.7%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.